Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
NEW YORK, Oct. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Manufacturing and Supply Partnering Terms and Agreements
The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world's biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all manufacturing and supply deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of manufacturing and supply dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply deal making as well as a discussion on the merits of the type of deal.
Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.
Chapters 5 and 6 provide a review of the leading manufacturing and supply deals since 2009. Deals are listed by headline value, signed by bigpharma and biobiotech, most active bigpharma and bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 8 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of manufacturing and supply deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapters 9 and 10 provide a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2009 for all pharma, biotech, device and diagnostics companies where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
In addition the report includes a comprehensive listing of all manufacturing and supply deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply alliances.
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
In-depth understanding of manufacturing and supply deal trends since 2009
Analysis of the structure of manufacturing and supply agreements with numerous real life case studies
Comprehensive access to over 2,300 actual manufacturing and supply deals entered into by the world's biopharma companies
Detailed access to actual manufacturing and supply deals entered into by the leading fifty bigpharma and bigbiotech companies
Comprehensive access to all manufacturing and supply deals entered since 2009
Insight into the terms included in a manufacturing and supply agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the manufacturing and supply trends and structure of deals entered into by pharma, biotech, device and diagnostics companies worldwide.
Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
Trends in manufacturing and supply dealmaking in the biopharma industry since 2009
Analysis of manufacturing and supply deal structure
Case studies of real-life manufacturing and supply deals
Access to over 2,300 manufacturing and supply deal records covering pharma, biotech, devices and diagnostics since 2009
The leading manufacturing and supply deals by value since 2009
Most active manufacturing and supply dealmakers since 2009
The leading manufacturing and supply partnering resources
In Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available deals are listed by:
Stage of development at signing
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Chapter 1 – Introduction
Chapter 2 – Trends in manufacturing and supply dealmaking
2.2. Difference between manufacturing and supply deals
2.3. Trends in manufacturing deals since 2009
2.4. Trends in supply deals since 2009
2.4.1. When supply can be useful
2.5. Attributes of pure manufacturing and supply deals
2.6. Attributes of manufacturing and supply in multi-component deals
2.7. Reasons for including manufacturing and supply options in a multicomponent deal
2.8. The future of manufacture and supply as part of multicomponent deals
Chapter 3 – Overview of manufacturing and supply deal structure
3.2. Pure versus multi-component manufacturing deals
3.3. Pure manufacturing agreement structure
3.3.1. Example manufacturing agreements
3.3.1.a. Case study 1: Amyris Brazil – Biomin Nutricao Animal Do Brasil
3.3.1.b. Case study 2: Patheon – Orexigen Therapeutics
3.4. Manufacturing rights as part of a wider alliance agreement
3.4.1. Example multicomponent manufacturing clauses
3.4.1.a. Case study 3: Agenus Bio – NewVac
3.4.1.b. Case study 4: Elite Pharmaceuticals – Hi-Tech Pharmacal
Chapter 4 – Overview of supply deal structure
4.2. Supply agreement structure
4.2.1. Example supply agreements
4.2.1.a. Case study 5: Omthera Pharmaceuticals – Catalent Pharma solutions
4.2.1.b. Case study 6: Endo Pharmaceuticals – Noramco
4.3. Supply rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 7: Auxilium Pharmaceuticals – Asahi Kasei
4.3.1.b. Case study 8: Durata Therapeutics - Hospira
Chapter 5 – Leading manufacturing deals
5.2. Top manufacturing deals by value
5.3. Most active manufacturing dealmakers
5.4. Big pharma manufacturing deal activity
5.5. Big biotech manufacturing deal activity
Chapter 6 – Leading supply deals
6.2. Top supply deals by value
6.3. Most active supply dealmakers
6.4. Bigpharma supply deal activity
6.4. Big biotech supply deal activity
Chapter 7 – Big pharma manufacturing and supply deals
7.2. How to use manufacturing and supply deals
7.3. Bigpharma company manufacturing and supply deal profiles
Chapter 8 – Bigbiotech manufacturing and supply deals
8.2. How to use bigbiotech partnering deals
8.3. Bigbiotech manufacturing and supply partnering company profiles
Chapter 9 – Manufacturing contracts directory
9.2. Company A-Z
9.3. By stage of development
9.4. By therapeutic target
9.5. By technology type
Chapter 10 – Supply contracts directory
10.2. Company A-Z
10.3. By stage of development
10.4. By therapeutic target
10.5. By technology type
About Wildwood Ventures
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Reports
View the accompanying appendices for:
Appendix 1 – Company A-Z manufacturing deals
Appendix 2 – By therapy area - manufacturing
Appendix 3 – By stage of development at signing - manufacturing
Appendix 4 – By technology type – manufacturing
Appendix 5 – Company A-Z - supply deals
Appendix 6 – By therapy area - supply
Appendix 7 – By stage of development at signing - supply
Appendix 8 – By technology type – supply
Appendix 9 –Dealmaking references
Appendix 10 – Resources
Appendix 11 – Deal type definitions
Appendix 12 – Example supply contract document
TABLE OF FIGURES
Figure 1: Definition of manufacturing and supply
Figure 2: Types of manufacturing agreement
Figure 3: Trends in manufacturing deal announcements, 2009-2013
Figure 4: Manufacturing deals signed by phase of development, 2009-2013
Figure 5: Trends in supply deal announcements, 2009-2013
Figure 6: Supply deals signed at what phase of development, 2009-2013
Figure 7: Situations where supply deals can prove useful
Figure 8: Components of the manufacturing deal structure
Figure 9: Components of the supply deal structure
Figure 10: Top manufacturing deals by value since 2009
Figure 11: Most active manufacturing dealmakers 2009-2013
Figure 12: Big pharma – top 50 – manufacturing deals 2009 to June 2013
Figure 13: Big pharma manufacturing deal frequency - 2009 to mid 2013
Figure 14: Big biotech – top 50 – manufacturing deals 2009 to June 2013
Figure 15: Top supply deals by value since 2009
Figure 16: Most active supply dealmakers 2009-2013
Figure 17: Bigpharma – top 50 – supply deals 2009 to 2013
Figure 18: Bigpharma supply deal frequency - 2009 to 2013
Figure 19: Big biotech – top 50 – supply deals 2009 to 2013
Figure 20: Big biotech supply deal frequency - 2009 to 2013
To order this report: Manufacturing and Supply Partnering Terms and Agreements
Contact Clare: email@example.com
Intl: +1 339-368-6001
©2012 PR Newswire. All Rights Reserved.